Hostname: page-component-7479d7b7d-c9gpj Total loading time: 0 Render date: 2024-07-08T12:16:33.684Z Has data issue: false hasContentIssue false
  • English
  • Français

The Opioid Industry Documents Archive: Advancing Public Health Through Industry Document Disclosure

Published online by Cambridge University Press:  31 May 2024

G. Caleb Alexander  and
Kate Tasker
G. Caleb Alexander
Affiliation:
CENTER FOR DRUG SAFETY AND EFFECTIVENESS, JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH, BALTIMORE, MARYLAND DEPARTMENT OF EPIDEMIOLOGY, JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH, BALTIMORE, MARYLAND DIVISION OF GENERAL INTERNAL MEDICINE, JOHNS HOPKINS MEDICINE, BALTIMORE, MARYLAND
Kate Tasker
Affiliation:
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO LIBRARY, SAN FRANCISCO
Get access Rights & Permissions [Opens in a new window]

Extract

More than twenty-five years after the first signs of potential harm, the US remains locked in the grip of an opioid epidemic, with more Americans dying from overdoses than ever before.1 Diversion of prescription opioids plays an important role in opioid-related harms. Much of the scientific and public health focus on diversion has been on end-users, given how commonly non-medical prescription opioid use occurs, as well as the proportion of individuals who report that their source of non-medical opioids was friends or family. However, diversion of opioids, as well as their rampant oversupply, can be discerned higher up the supply chain, including among wholesalers, pharmacies and rogue prescribers whose behavior may trigger well-described “flags” warranting further evaluation and action.

Keywords

Opioid EpidemicOpioid IndustryDigital Archives
Type
Commentary
Information
Journal of Law, Medicine & Ethics , Volume 52 , Issue 1 , Spring 2024 , pp. 133 - 135
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

“Provisional Data Shows U.S. Drug Overdose Deaths Top 100,000 in 2022,” Centers for Disease Control and Prevention, May 18, 2023, available at <https://blogs.cdc.gov/nchs/2023/05/18/7365/#:~:text=The%20only%20state%20in%20which,82%2C310%20in%20the%20previous%20year> (last visited January 29, 2024).+(last+visited+January+29,+2024).>Google Scholar
Alexander, G. C. et al., “The Opioid Industry Documents Archive: A Living Digital Repository,” American Journal of Public Health 112 (2022): 1126–1129, PMID: 35830677.Google Scholar
Lentacker, A., Pham, K., and Chernesky, J. M., “Diverting Data and Drugs: A Narrative Review of the Mallinckrodt Documents,” Journal of Law, Medicine & Ethics 52, no. 1 (2024): 118–132.Google Scholar
Bero, L., “Implications of the Tobacco Industry Documents for Public Health and Policy,” Annual Review of Public Health 24 (2003): 267–88, doi: 10.1146/annurev.publhealth.24.100901.140813, Epub 2001 Nov 6. PMID: 12415145.Google ScholarPubMed
Mallinckrodt Injunctive Relief Term Sheet, Case 20-50850-JTD, Doc 196-1, filed 01/08/21, available at <https://www.mallinckrodt.com/globalassets/documents/corporate/active_96917799_1_operating-injunction.pdf> (Accessed January 29, 2024).+(Accessed+January+29,+2024).>Google Scholar
The Lancet, “Unravelling the Commercial Determinants of Health,” The Lancet 401 (2023): 1131, doi: 10.1016/S0140-6736(23)00590-1, Epub 2023 Mar 23. PMID: 36966781.Google Scholar